Literature DB >> 19285990

Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody.

Elena A Kashentseva1, Joanne T Douglas, Kurt R Zinn, David T Curiel, Igor P Dmitriev.   

Abstract

The purpose of the current study was to alter the broad native tropism of human adenovirus for virus targeting to c-erbB2-positive cancer cells. First, we engineered a single-chain antibody (scFv) against the c-erbB2 oncoprotein into minor capsid protein IX (pIX) of adenovirus serotype 5 (Ad5) in a manner commensurate with virion integrity and binding to the soluble extracellular c-erbB2 domain. To ablate native viral tropism and facilitate binding of the pIX-incorporated scFv to cellular c-erbB2, we replaced the Ad5 fiber with the Ad41 short (41s) fiber devoid of all known cell-binding determinants. The resultant Ad5F41sIX6.5 vector demonstrated increased cell binding and gene transfer as compared to the Ad5F41s control; however, this augmentation of virus infectivity was not c-erbB2 specific. Incorporation of a six-histidine (His(6)) peptide into the C-terminus of the 41s fiber protein resulted in markedly increased Ad5F41s6H infectivity in 293AR cells, which express a membrane-anchored scFv against the C-terminal oligohistidine tag, as compared to the Ad5F41s vector and the parental 293 cells. These data suggested that a 41s-fiber-incorporated His(6) tag could serve for attachment of an adapter protein designed to guide Ad5F41s6H infection in a c-erbB2-specific manner. We therefore engineered a bispecific scFv diabody (scDb) combining affinities for both c-erbB2 and the His(6) tag and showed its ability to provide up to 25-fold increase of Ad5F41s6H infectivity in c-erbB2-positive cells. Thus, Ad5 fiber replacement by a His(6)-tagged 41s fiber coupled with virus targeting mediated by an scDb adapter represents a promising strategy to confer Ad5 vector tropism for c-erbB2-positive cancer cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19285990      PMCID: PMC2696239          DOI: 10.1016/j.jmb.2009.03.016

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  100 in total

1.  CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors.

Authors:  R Alemany; D T Curiel
Journal:  Gene Ther       Date:  2001-09       Impact factor: 5.250

Review 2.  The influence of adenovirus fiber structure and function on vector development for gene therapy.

Authors:  Stuart A Nicklin; Eugene Wu; Glen R Nemerow; Andrew H Baker
Journal:  Mol Ther       Date:  2005-09       Impact factor: 11.454

3.  Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting.

Authors:  Samuel K Campos; Michael A Barry
Journal:  Virology       Date:  2006-02-28       Impact factor: 3.616

4.  Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.

Authors:  Diane M Roberts; Anjali Nanda; Menzo J E Havenga; Peter Abbink; Diana M Lynch; Bonnie A Ewald; Jinyan Liu; Anna R Thorner; Patricia E Swanson; Darci A Gorgone; Michelle A Lifton; Angelique A C Lemckert; Lennart Holterman; Bing Chen; Athmanundh Dilraj; Angela Carville; Keith G Mansfield; Jaap Goudsmit; Dan H Barouch
Journal:  Nature       Date:  2006-04-16       Impact factor: 49.962

5.  Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons.

Authors:  Shaoheng Ni; Kathrin Bernt; Anuj Gaggar; Zong-Yi Li; Hans-Peter Kiem; André Lieber
Journal:  Hum Gene Ther       Date:  2005-06       Impact factor: 5.695

6.  Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting.

Authors:  Neus Bayo-Puxan; Manel Cascallo; Alena Gros; Meritxell Huch; Cristina Fillat; Ramon Alemany
Journal:  J Gen Virol       Date:  2006-09       Impact factor: 3.891

7.  Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for functional display on the virion.

Authors:  Jing Li; Long Le; Don A Sibley; J Michael Mathis; David T Curiel
Journal:  Virology       Date:  2005-08-01       Impact factor: 3.616

8.  Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation.

Authors:  John W Schoggins; Marcelo Nociari; Nicola Philpott; Erik Falck-Pedersen
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Selective induction of tumor-associated antigens in murine pulmonary vasculature using double-targeted adenoviral vectors.

Authors:  M Everts; S-A Kim-Park; M A Preuss; M J Passineau; J N Glasgow; A V Pereboev; P J Mahasreshti; W E Grizzle; P N Reynolds; D T Curiel
Journal:  Gene Ther       Date:  2005-07       Impact factor: 5.250

10.  Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling.

Authors:  Long P Le; Helen N Le; Igor P Dmitriev; Julia G Davydova; Tatyana Gavrikova; Seiji Yamamoto; David T Curiel; Masato Yamamoto
Journal:  J Natl Cancer Inst       Date:  2006-02-01       Impact factor: 13.506

View more
  8 in total

1.  Bispecific adapter-mediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells.

Authors:  Hyunjung Baek; Hiroaki Uchida; Kyungok Jun; Jae-Hong Kim; Masahide Kuroki; Justus B Cohen; Joseph C Glorioso; Heechung Kwon
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

2.  Inclusion of the murine IgGκ signal peptide increases the cellular immunogenicity of a simian adenoviral vectored Plasmodium vivax multistage vaccine.

Authors:  Jairo A Fonseca; Jessica N McCaffery; Juan Caceres; Elena Kashentseva; Balwan Singh; Igor P Dmitriev; David T Curiel; Alberto Moreno
Journal:  Vaccine       Date:  2018-04-12       Impact factor: 3.641

3.  A prime-boost immunization regimen based on a simian adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice.

Authors:  Jairo A Fonseca; Jessica N McCaffery; Elena Kashentseva; Balwan Singh; Igor P Dmitriev; David T Curiel; Alberto Moreno
Journal:  Vaccine       Date:  2017-05-05       Impact factor: 3.641

4.  Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor.

Authors:  T J Harvey; D Burdon; L Steele; N Ingram; G D Hall; P J Selby; R G Vile; P A Cooper; S D Shnyder; J D Chester
Journal:  Gene Ther       Date:  2010-04-22       Impact factor: 5.250

5.  Molecular imaging of biological gene delivery vehicles for targeted cancer therapy: beyond viral vectors.

Authors:  Jung-Joon Min; Vu H Nguyen; Sanjiv S Gambhir
Journal:  Nucl Med Mol Imaging       Date:  2010-02-26

6.  Increasing the efficacy of oncolytic adenovirus vectors.

Authors:  Karoly Toth; William S M Wold
Journal:  Viruses       Date:  2010-08-27       Impact factor: 5.818

7.  Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds.

Authors:  Michael Behr; Johanna K Kaufmann; Patrick Ketzer; Sarah Engelhardt; Martin Mück-Häusl; Pamela M Okun; Gabriele Petersen; Frank Neipel; Jessica C Hassel; Anja Ehrhardt; Alexander H Enk; Dirk M Nettelbeck
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

Review 8.  Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies.

Authors:  Tabitha G Cunliffe; Emily A Bates; Alan L Parker
Journal:  Cancers (Basel)       Date:  2020-11-11       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.